Onconetix (ONCO) Registration Filing summary

Company overview and business model

• Commercial-stage biotechnology company focused on men's health and oncology, with primary assets Proclarix (prostate cancer diagnostic) and ENTADFI (BPH therapy).

• Proclarix is CE-marked in the EU and marketed via partnerships; U.S. commercialization is planned through Labcorp as an LDT.

• ENTADFI commercialization is currently paused due to resource constraints and strategic review; company is considering a sale or other alternatives.

• Recent strategic shift away from vaccine R&D to focus on commercial assets and potential monetization of non-core programs.

Financial performance and metrics

• For the year ended December 31, 2023, reported revenue was $58,465, with a net loss of $37.4 million and an accumulated deficit of $56.8 million.

• As of March 31, 2024, cash was $4.5 million, working capital deficit was $15.1 million, and accumulated deficit was $67.9 million.

• Proteomedix (acquired Q4 2023) had 2022 revenue of $392,460 and a net loss of $2.0 million; for the nine months ended September 30, 2023, revenue was $2.1 million with net income of $319,188.

• Company expects to continue incurring significant operating losses and will require additional capital to sustain operations beyond Q3 2024.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders.

• Any proceeds from the exercise of warrants/options will be used for general corporate and working capital purposes.

• Capital allocation is focused on commercializing Proclarix, supporting ongoing operations, and meeting existing obligations, including debt and milestone payments.